Too Much Weight Loss With Retatrutide? Transgender Doc Sued; Ice Age Growth Disorder
(MedPage Today) — Some participants in a weight-loss trial of retatrutide, an investigational triple-hormone receptor agonist, dropped out because they thought they were losing too much weight. (New York Times)
Meanwhile, UBT251, another investigational…
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
Following Monday’s clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist.
Novo Nordisk to slash Wegovy and Ozempic prices starting in 2027
Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.
STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more
The Trump administration released detailed guidance for approving the first bespoke medicines crafted to treat individual patient mutations
Novo Returns to Pre-Wegovy Valuation as Lilly Makes History as First Ever $1T Pharma
Eli Lilly’s win in a head-to-head trial drove Novo Nordisk’s market cap to pre-Wegovy levels not long after the victor became the first pharma company to top a $1 trillion valuation. It seems one company can do no right, while the other can do no wrong.
FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
Audience: Health Care Professional, Consumer January 13, 2026
FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety…
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…
GLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.
What’s next for GLP-1s?
Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other chronic diseases—many with few treatment options—such as heart failure, chronic liver disease, obstructive sleep apnea, and even substance use disorders.